1.Zhou Y,Ji M, Xia Y, Han X, Li M, Li W, Sun T, Zhang J, Lu F, Sun Y, Liu N, Li J, Ma D, Ye J, Ji C.Silencing of IRF8 Mediated by m6A Modification Promotes the Progression of T-Cell Acute Lymphoblastic Leukemia. Adv Sci (Weinh). 2023;10(2):e2201724.(共同第一)
2.Jia R, Sun T, Zhao X, Li G, Xia Y, Zhou Y, Li W, Li W, Ma D, Ye J,Ji M, Ji C.DEX-Induced SREBF1 Promotes BMSCs Differentiation into Adipocytes to Attract and Protect Residual T-Cell Acute Lymphoblastic Leukemia Cells After Chemotherapy. Adv Sci (Weinh). 2023;10(19):e2205854.(共同通讯)
3.Yuqing Rao, Guopeng Xu, Zhihua Zhang, Weijie Wang, Chengmei Zhang, Mingwen Zhao, Yuanyuan Qu, Weifeng Li,Min Ji, Yanguo Liu, Yong-Qiang Li.Coupling doping and localized surface plasmon resonance toward acidic pH-preferential catalase-like nanozyme for oxygen-dominated synergistic cancer therapy. Chemical Engineering Journal.2023;465:142961.(共同通讯)
4.Zhou Y, Guan L, Li W, Jia R, Jia L, Zhang Y, Wen X, Meng S, Ma D, Zhang N,Ji M, Liu Y, Ji C.DT7 peptide-modified lecithin nanoparticles co-loaded with γ-secretase inhibitor and dexamethasone efficiently inhibit T-cell acute lymphoblastic leukemia and reduce gastrointestinal toxicity.Cancer Lett. 2022;533:215608.(共同通讯)
5.Li W,Ji M, Lu F, Pang Y, Dong X, Zhang J, Li P, Ye J, Zang S, Ma D, Ji C.. Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia.Cell Death Dis. 2018 Aug 28;9(9):855.(共同第一)
6.Ji M, Li J, Yu H, Ma D, Ye J, Sun X, Ji C.Simultaneous targeting of MCL1 and ABCB1 as a novel strategy to overcome drug resistance in human leukaemia.Br J Haematol. 2009 Jun;145(5):648-56.(第一作者)
7.Xiong Y, Li Z,Ji M, Tan AC, Bemis J, Tse JV, Huang G, Park J, Ji C, Chen J, Bemis LT, Bunting KD,Tse W. MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML. Br J Haematol. 2011 Jun;153(6):753-7.(共同第一)
8.Jia R,Ji M, Li G, Xia Y, Guo S, Li P, Sun Y, Lu F, Zhang J, Zang S, Yan S, Ye J, Xue F, Ma D, Sun T, Ji C.Subclones of bone marrow CD34+cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy. Cancer. 2022;128(22):3929-3942.(共同第一)
9.Li B, Jia R, Li W, Zhou Y, Guo D, Teng Q, Du S, Li M, Li W, Sun T, Ma D,Ji M, Ji C.PAK1 Mediates Bone Marrow Stromal Cell-Induced Drug Resistance in Acute Myeloid Leukemia via ERK1/2 Signaling Pathway. Front Cell Dev Biol. 2021;9:686695.(通讯作者)
10.Zhang Y,Ji M, Zhao JY, Wang HF, Wang CW, Li W, Ye JJ, Lu F, Lin LH, Gao YT, Jin J, Li L, Ji CY, Ballesteros J, Zhu HH.Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy. Front Oncol. 2022;11:793773.(共同第一)
11.Liu Q, Li W, Zhou Y, Jian J, Han S, Liu C, Li W, Zhu X, Ma D,Ji M, Ji C.PRKD2 Promotes Progression and Chemoresistance of AML via Regulating Notch1 Pathway. Onco Targets Ther. 2019;12:10931-10941.(通讯作者)
